Giselle Sholler

This phase II trial is testing whether adding the drug naxitamab (Danyelza) to standard chemotherapy improves outcomes for children newly diagnosed with high-risk neuroblastoma. About 93 participants will receive naxitamab during five cycles of induction chemo. The goal is to see…

This study tests a drug called DFMO (eflornithine) as a maintenance therapy to prevent medulloblastoma, a type of brain cancer, from returning in children. It includes 118 participants aged 0-21 with high-risk or relapsed forms of the disease. The goal is to see if DFMO can exten…

This study tests a new pill called tipifarnib combined with an FDA-approved drug, naxitamab, for people with neuroblastoma that has come back or not responded to treatment. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. The trial is for…

This study is for children newly diagnosed with high-risk neuroblastoma, a rare and aggressive nerve cancer. It uses genetic testing to choose personalized chemotherapy, then tests whether adding the drug DFMO to standard immunotherapy helps prevent relapse. About 500 children wi…

This expanded access program provides the drug DFMO to children and young adults up to age 30 with rare relapsed tumors such as neuroblastoma or medulloblastoma. The goal is to control the disease by targeting specific genetic markers. Participants take DFMO by mouth twice daily,…

This study is creating a large database of tumor samples and health information from children and young adults with cancer. Researchers will analyze the genetic makeup of these tumors to find patterns and potential new treatments. The goal is to better understand pediatric cancer…